AS
BMRN icon

AM Squared’s BioMarin Pharmaceuticals BMRN Stock Holding History

AM Squared’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$98.4K Buy
1,400
+600
+75% +$50.2K 0.22% 36
2024
Q2 		$65.9K Buy
+800
New +$66.6K 0.17% 49

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

AM Squared's BMRN Position: Q3 2024 in Review

AM Squared increased its BioMarin Pharmaceuticals (BMRN) stake by 75% in Q3 2024, buying an estimated $50.2K and bringing the position to 1,400 shares worth $98.4K. The position accounts for 0.22% of the portfolio, ranked #36.

AM Squared first reported a position in BMRN in Q2 2024 and has held it in 2 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • AM Squared held 1,400 shares of BioMarin Pharmaceuticals worth $98.4K as of Q3 2024.
  • AM Squared bought 600 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $50.2K.
  • BioMarin Pharmaceuticals made up 0.22% of AM Squared's portfolio in Q3 2024, its #36 holding.
  • AM Squared first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.